HB 4149 (A-Engrossed), legislation related to PBM Reforms, was amended and passed the House Behavioral Health & Health Care this week. Given the amendments, Chair Rob Nosse (R) stated he will be convening a workgroup after this year’s regular session and outlined issues to be addressed to advance additional PBM reforms in the state.
Also in Oregon, SB 1506 (A-Engrossed) passed the Senate and was assigned to the House Behavioral Health & Health Care Committee. It is scheduled for a Work Session on February 28. This bill would allow a pharmacist to test and prescribe, dispense and administer treatment for SAVS-CoV-2 consistent with protocols adopted by the State Board of Pharmacy by rule. It would also permit a pharmacist to delegate to a pharmacy technician or an intern under the pharmacist’s supervision the administrative and technical tasks of performing a SARS-CoV-2 CLIA-waived test. Finally, the bill would require payment for these services effective October 1, 2024, with a sunset date of June 30, 2026.
Also in Oregon, HB 4113 (A-Engrossed), legislation requiring all amounts paid by an enrollee or paid by another person on behalf of the enrollee toward the cost of a covered prescription drug be included when calculating the enrollee’s contribution to an out-of-pocket maximum, deductible, copayment, coinsurance or other cost-sharing requirements, passed the House Behavioral Health & Health Care Committee.
Also in Oregon, HB 4010 (A-Engrossed), legislation that includes language specifying that the flavoring of a prescription drug is not compounding, passed the House Behavioral Health & Health Care Committee.
Finally in Oregon, the Oregon Health Authority’s Immunization Policy Advisory Team will meet on March 7 via Zoom. The final agenda will be available at the meeting or via email request three days before the meeting date by contacting imm.info@odhsoha.oregon.gov. Participation via Zoom requires advance registration using this link. Those who register will receive a confirmation email with additional information. Note: this information is necessary to join the meeting.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.